Your browser doesn't support javascript.
loading
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Nitz, U A; Gluz, O; Christgen, M; Grischke, E-M; Augustin, D; Kuemmel, S; Braun, M; Potenberg, J; Kohls, A; Krauss, K; Stefek, A; Schumacher, C; Forstbauer, H; Reimer, T; Fischer, H; Liedtke, C; Wuerstlein, R; Schumacher, J; Kates, R; Kreipe, H; Harbeck, N.
Afiliación
  • Nitz UA; West German Study Group GmbH, Moenchengladabach; Evangelical Hospital Johanniter Bethesda, Breast Center Niederrhein, Moenchengladbach.
  • Gluz O; West German Study Group GmbH, Moenchengladabach; Evangelical Hospital Johanniter Bethesda, Breast Center Niederrhein, Moenchengladbach; University of Cologne, Cologne. Electronic address: oleg.gluz@wsg-online.com.
  • Christgen M; Institute of Pathology, Medical School Hannover, Hannover.
  • Grischke EM; Department of Gynecology and Obstetrics, University Clinics Tuebingen, Tuebingen.
  • Augustin D; Breast Center Ostbayern, Deggendorf.
  • Kuemmel S; Breast Center, Clinics Essen-Mitte, Essen.
  • Braun M; Rotkreuz Clinics Munich Breast Center, Munich.
  • Potenberg J; Department of Oncology Evangelical Waldkrankenhaus Berlin, Berlin.
  • Kohls A; Department of Gynecology and Obstetrics, Evangelical Hospital, Ludwigsfelde.
  • Krauss K; Department of Gynecology and Obstetrics, University Clinics RWTH, Aachen.
  • Stefek A; Breast Center, Evangelical Hospital Johanniter, Stendal.
  • Schumacher C; Breast Center, St. Elisabeth Hospital Cologne, Cologne.
  • Forstbauer H; Oncology Practice Network, Troisdorf.
  • Reimer T; Department of Gynecology and Obstetrics, University Clinics Rostock, Suedstadt.
  • Fischer H; Breast Center, Evangelical Hospital Gelsenkirchen, Gelsenkirchen.
  • Liedtke C; Department of Gynecology and Obstetrics, University Clinics Schleswig-Holstein/Campus Luebeck, Luebeck; Charite Berlin.
  • Wuerstlein R; Breast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, Munich.
  • Schumacher J; Palleos Healthcare, Statistics, Wiesbaden, Germany.
  • Kates R; West German Study Group GmbH, Moenchengladabach.
  • Kreipe H; University of Cologne, Cologne.
  • Harbeck N; West German Study Group GmbH, Moenchengladabach; Breast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, Munich.
Ann Oncol ; 28(11): 2768-2772, 2017 Nov 01.
Article en En | MEDLINE | ID: mdl-28945833
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor ErbB-2 / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article